Ken Griffin’s Galectin Therapeutics GALT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $810K | Buy |
+290,360
| New | +$883K | ﹤0.01% | 8158 |
|
|
2025
Q4 | – | Sell |
-71,306
| Closed | -$375K | – | 13145 |
|
|
2025
Q3 | $302K | Sell |
71,306
-31,991
| -31% | -$120K | ﹤0.01% | 10361 |
|
|
2025
Q2 | $218K | Buy |
+103,297
| New | +$155K | ﹤0.01% | 10494 |
|
|
2024
Q3 | – | Sell |
-823
| Closed | -$2.02K | – | 14559 |
|
|
2024
Q2 | $1.86K | Sell |
823
-23,698
| -97% | -$72K | ﹤0.01% | 13768 |
|
|
2024
Q1 | $58.6K | Buy |
24,521
+17,511
| +250% | +$33.1K | ﹤0.01% | 12023 |
|
|
2023
Q4 | $11.6K | Buy |
+7,010
| New | +$13.6K | ﹤0.01% | 13034 |
|
|
2023
Q3 | – | Sell |
-428
| Closed | -$616 | – | 14571 |
|
|
2023
Q2 | $616 | Sell |
428
-850
| -67% | -$1.44K | ﹤0.01% | 14078 |
|
|
2023
Q1 | $2.68K | Sell |
1,278
-82,356
| -98% | -$133K | ﹤0.01% | 14117 |
|
|
2022
Q4 | $94.5K | Buy |
83,634
+65,494
| +361% | +$87.2K | ﹤0.01% | 11302 |
|
|
2022
Q3 | $29K | Buy |
+18,140
| New | +$33.9K | ﹤0.01% | 11919 |
|
|
2022
Q1 | – | Sell |
-43,382
| Closed | -$84K | – | 13938 |
|
|
2021
Q4 | $90K | Buy |
43,382
+18,950
| +78% | +$54.1K | ﹤0.01% | 12815 |
|
|
2021
Q3 | $95K | Buy |
+24,432
| New | +$82.8K | ﹤0.01% | 12937 |
|
|
2021
Q1 | – | Sell |
-19,333
| Closed | -$43.3K | – | 13346 |
|
|
2020
Q4 | $43K | Buy |
+19,333
| New | +$50.7K | ﹤0.01% | 10618 |
|
|
2020
Q3 | – | Sell |
-15,383
| Closed | -$43.1K | – | 10282 |
|
|
2020
Q2 | $47K | Sell |
15,383
-36,220
| -70% | -$91.1K | ﹤0.01% | 9331 |
|
|
2020
Q1 | $101K | Buy |
51,603
+40,512
| +365% | +$98.6K | ﹤0.01% | 8628 |
|
|
2019
Q4 | $32K | Sell |
11,091
-7,955
| -42% | -$27.6K | ﹤0.01% | 8854 |
|
|
2019
Q3 | $70K | Buy |
+19,046
| New | +$68.8K | ﹤0.01% | 8612 |
|
|
2019
Q2 | – | Sell |
-20,411
| Closed | -$88.4K | – | 9399 |
|
|
2019
Q1 | $104K | Sell |
20,411
-316
| -2% | -$1.52K | ﹤0.01% | 8540 |
|
|
2018
Q4 | $71K | Buy |
+20,727
| New | +$99K | ﹤0.01% | 8389 |
|
|
2018
Q3 | – | Sell |
-23,399
| Closed | -$129K | – | 9380 |
|
|
2018
Q2 | $149K | Sell |
23,399
-44,147
| -65% | -$215K | ﹤0.01% | 8071 |
|
|
2018
Q1 | $320K | Buy |
+67,546
| New | +$315K | ﹤0.01% | 6644 |
|
|
2017
Q3 | – | Sell |
-13,300
| Closed | -$26.4K | – | 7686 |
|
|
2017
Q2 | $33K | Sell |
13,300
-21,409
| -62% | -$57K | ﹤0.01% | 7183 |
|
|
2017
Q1 | $80K | Buy |
+34,709
| New | +$52.3K | ﹤0.01% | 6930 |
|
|
2016
Q4 | – | Sell |
-25,771
| Closed | -$22.9K | – | 7456 |
|
|
2016
Q3 | $29K | Buy |
25,771
+11,935
| +86% | +$21.2K | ﹤0.01% | 6968 |
|
|
2016
Q2 | $20K | Buy |
+13,836
| New | +$20.3K | ﹤0.01% | 6603 |
|
|
2015
Q4 | – | Sell |
-8,809
| Closed | -$21K | – | 8869 |
|
|
2015
Q3 | $21K | Sell |
8,809
-1,957
| -18% | -$4.62K | ﹤0.01% | 8121 |
|
|
2015
Q2 | $29K | Buy |
+10,766
| New | +$32.5K | ﹤0.01% | 7979 |
|
|
2015
Q1 | – | Sell |
-6,906
| Closed | -$24K | – | 8627 |
|
|
2014
Q4 | $24K | Sell |
6,906
-13,112
| -66% | -$57.9K | ﹤0.01% | 7669 |
|
|
2014
Q3 | $101K | Buy |
20,018
+17,320
| +642% | +$135K | ﹤0.01% | 6406 |
|
|
2014
Q2 | $37K | Buy |
+2,698
| New | +$33.6K | ﹤0.01% | 6946 |
|
Other funds holding GALT
VCM
WANY
Ken Griffin's GALT Position: Q1 2026 in Review
Ken Griffin opened a new position in Galectin Therapeutics (GALT) in Q1 2026: 290,360 shares worth $810K. The stake represents ﹤0.01% of the portfolio and ranks #8158 among its holdings. This is a return to the name: Ken Griffin previously reported a position in GALT as recently as Q3 2025.
Ken Griffin first reported a position in GALT in Q2 2014 and has held it in 30 quarters since. 98 funds tracked by Wall St. Rank hold GALT as of Q1 2026.
- Ken Griffin held 290,360 shares of Galectin Therapeutics worth $810K as of Q1 2026.
- Galectin Therapeutics was a new Ken Griffin position in Q1 2026.
- Galectin Therapeutics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #8158 holding.
- Ken Griffin first reported a position in Galectin Therapeutics in Q2 2014 and has held it in 30 quarters since.
- 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.